A case of linear IgA disease with IgA antibodies to type VII collagen demonstrated by immunofluorescence overlay antigen mapping

European Journal of Dermatology - Tập 32 - Trang 553-554 - 2023
Shohei Kitayama1, Teruhiko Makino1, Masao Hayashi1, Fumina Furukawa1, Ryotaro Torai1, Megumi Mizawa1, Norito Ishii2, Takashi Hashimoto3, Tadamichi Shimizu1
1Department of Dermatology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
2Department of Dermatology, Kurume University School of Medicine, Kurume, Japan
3Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan

Tài liệu tham khảo

Hashimoto T, Yamagami J, Zone JJ. History, diagnosis, pathogenesis, and nomenclature in sublamina densa-type linear IgA disease. JAMA Dermatol 2021; 157: 907–9. Tsuchisaka A, Ohara K, Ishii N, Nguyen NT, Marinkovich P, Hashimoto T. Type VII collagen is the major autoantigen for sublamina densa-type linear IgA bullous dermatosis. J Invest Dermatol 2015; 135: 626–9. Becker M, Schumacher N, Schmidt E, Zillikens D, Sadik CD. Evaluation and comparison of clinical and laboratory characteristics of patients with IgA epidermolysis bullosa acquisita, linear IgA bullous dermatosis, and IgG epidermolysis bullosa acquisita. JAMA Dermatol 2021; 157: 917–23. Wozniak K, Hashimoto T, Ishii N, Koga H, Huczek M, Kowalewski C. Fluorescence overlay antigen mapping using laser scanning confocal microscopy differentiates linear IgA bullous dermatosis from epidermolysis bullosa acquisita mediated by IgA. Br J Dermatol 2013; 168: 634–8. Montagnon CM, Lehman JS, Murrell DF, Camilleri MJ, Tolkachjov SN. Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy. J Am Acad Dermatol 2021; 85: 18–27. Hayakawa T, Hirako Y, Teye K, et al. Unique mouse monoclonal antibodies reactive with maturation-related epitopes on type VII collagen. Exp Dermatol 2017; 26: 811–9. Gribaleva E, van der Molen SM, Kramer D, et al. Subepidermal type VII collagen speckles as an additional clue for diagnosing epidermolysis bullosa acquisita by salt-split skin serum analysis. J Eur Acad Dermatol Venereol 2022; 36: e384–6. Iwata H, Vorobyev A, Koga H, et al. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis 2018; 13: 153. Bis S, Maguiness SM, Gellis SE, et al. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome associated with neonatal epidermolysis bullosa acquisita. Pediatr Dermatol 2015; 32: e74–7. Vodegel RM, de Jong MC, Pas HH, Jonkman MF. IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature. J Am Acad Dermatol 2002; 47: 919–25.